Company intelligence / Profile preview

ProMedTek

Scottsdale, Arizona, United Statespromedtek.com ↗

Ownership: Private
Development stage: Commercial

Overview

ProMedTek’s flagship product, Replexa+, is FDA-cleared for pain relief, muscle spasm reduction, increased range of motion, and improved blood flow. The company has expanded its footprint into Veterans Affairs and Department of Defense medical facilities since 2016 with positive outcomes reported for veterans and active military personnel.

Therapeutic areas: CardiovascularRheumatologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Replexa+

Commercial

Indications: Pain management, Muscle spasm, Joint contractures, Tissue blood flow improvement

Partnerships

U.S. Department of Veterans Affairs Medical System (VA)U.S. Department of Defense Medical Facilities

Beyond the preview

Go deeper on ProMedTek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProMedTek.

Explore the full profile